Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors
- 1 September 2017
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (17) , 4034-4038
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Parkinson's diseaseThe Lancet, 2015
- Disease‐modifying strategies for Parkinson's diseaseMovement Disorders, 2015
- LRRK2 Pathways Leading to NeurodegenerationCurrent Neurology and Neuroscience Reports, 2015
- Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson DiseaseNeurotherapeutics, 2014
- Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's diseaseTrends in Pharmacological Sciences, 2012
- LRRK2 and Parkinson DiseaseArchives of Neurology, 2010
- Neurobiology and treatment of Parkinson's diseaseTrends in Pharmacological Sciences, 2009
- A review of Parkinson's diseaseBritish Medical Bulletin, 2008
- PROJECTED NUMBER OF PEOPLE WITH PARKINSON DISEASE IN THE MOST POPULOUS NATIONS, 2005 THROUGH 2030Neurology, 2007
- Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic PathologyNeuron, 2004